Annexon Presents Update On ARCHER II Global Registrational Program In Geographic Atrophy; Topline Data Expected In Second Half 2026
Portfolio Pulse from Benzinga Newsdesk
Annexon, Inc. (NASDAQ:ANNX) has initiated patient dosing in its Phase 3 ARCHER II trial for ANX007, targeting geographic atrophy (GA). Topline data is expected in the second half of 2026. Phase 2 data showed significant vision and structural protection, supporting ANX007's potential in GA treatment.
August 05, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annexon has initiated patient dosing in its Phase 3 ARCHER II trial for ANX007, with topline data expected in the second half of 2026. Phase 2 results showed significant vision and structural protection, indicating strong potential for ANX007 in treating geographic atrophy.
The initiation of the Phase 3 trial and positive Phase 2 data are significant milestones for Annexon. These developments suggest strong potential for ANX007 in treating geographic atrophy, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100